“The difference between good pharmaceutical investing and great pharmaceutical investing isn’t access to data—it’s the ability to decode the science behind the billion-dollar breakthroughs.”
Unlocking the Secrets Behind 2024’s Top-Selling Drugs
The pharmaceutical industry generated over $154 billion from just the top 10 best-selling drugs in 2024—a staggering 53% increase from 2019. But behind these massive numbers lies a complex web of scientific research, clinical trials, and competitive intelligence that traditional analysis methods struggle to decode. This is where AllSci’s revolutionary scientific intelligence platform transforms how pharma and biotech investors identify opportunities and assess risks.
The $154 Billion Question: What Makes a Blockbuster Drug?
The 2024 top 10 best-selling drugs generated $154.888 billion in aggregate sales, up 6.5% from $145.495 billion in 2023. Leading this pack is Merck’s Keytruda (pembrolizumab) at $29.482 billion, followed by Bristol Myers Squibb and Pfizer’s Eliquis at $20.699 billion, and Novo Nordisk’s breakthrough diabetes drug Ozempic at $18.655 billion.
But these numbers only tell part of the story. The real value lies in understanding the scientific foundations, competitive landscapes, and emerging threats that will shape these drugs’ futures—insights that AllSci’s comprehensive platform delivers at unprecedented scale.
Deep-Dive Analysis: Leveraging AllSci’s 12M+ Hypotheses Database
Case Study 1: The GLP-1 Revolution – Ozempic and Mounjaro
Ozempic saw a remarkable 25.8% growth to $18.655 billion, while Eli Lilly’s Mounjaro exploded with 123.5% growth to $11.540 billion. Using AllSci’s platform, investors can:
Hypothesis Discovery & Testing:
- Access our proprietary database of 12M+ scientific hypotheses to understand the evolving research around GLP-1 receptor agonists
- Test hypotheses about combination therapies, new indications, and competitive threats
- Identify research gaps that could represent untapped opportunities
Clinical Trial Intelligence:
- Monitor our 500K+ clinical trials database for emerging GLP-1 competitors
- Track pipeline developments across weight management, diabetes, and cardiovascular applications
- Use AERIS AI to predict potential market disruptions based on trial outcomes
Case Study 2: Cancer Immunotherapy Dominance – Keytruda’s Continued Growth
Keytruda maintained its top position with $29.482 billion in sales, growing 17.9% year-over-year. AllSci’s platform reveals why:
Competitive Intelligence & Benchmarking:
- Compare research output against competitors
- Monitor evolving research areas in combination immunotherapies
- Track thought leaders and key researchers driving innovation in the space
Visual Discovery & Mapping:
- Use semantic maps to visualize relationships between PD-1/PD-L1 pathways and emerging targets
- Identify combination therapy opportunities through interactive scientific mapping
- Discover gaps in current research that could represent investment opportunities
Our AI-powered research assistant leverages AllSci’s massive database to answer complex investment questions:
“What are the biggest threats to Dupixent’s $15.125 billion market?” AERIS can instantly analyze: